Skip to content

Nektar/Daiichi breast cancer med gets nod from Euro panel

July 23, 2017

European regulators on Friday recommended against granting approval to a breast cancer drug being developed by Nektar Therapeutics and Daiichi Sankyo’s German unit.

The European Medicines Agency (EMA) said its committee of experts refused authorization to market the investigational drug, Onzeald, as a first-line treatment for adults with advanced breast cancer who have already received other treatment.

One of the main concerns raised by the committee was that the benefit of Onzeald to treat breast cancer that had spread to the brain had not been “sufficiently demonstrated”.

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: